MIRA (MIRA Pharmaceuticals Inc.) stock: $0.86, $36.3M market cap, $8.1M cash, $28.2M EV, $43.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$0.86
Market cap
$36.3M
Cash
$8.1M
Enterprise value
$28.2M
Balance sheet
Cash
$8.1M
Debt
$0.0M
Net cash
$8.1M
Enterprise value
$28.2M
Basic shares
42.0M shares
Fully diluted shares
50.0M shares
Fully diluted market cap
$43.0M
Cash per share
$0.19
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading MIRA daily closes…
Loading price history…
Pipeline assets
Ketamir-2
Phase 1 · ActiveModality: oral small molecule
Target NMDA receptor
Indications
chemotherapy-induced peripheral neuropathy(Stage not disclosed)
Catalysts
— None
Status note Oral selective NMDA receptor modulator. Phase 1 single- and multiple-ascending-dose studies in healthy volunteers completed; active IND.
MIRA-55
Preclinical · ActiveModality: oral small molecule
Target CB2
Indications
chronic inflammatory pain(Stage not disclosed)
Status note Potential non-opioid therapy. Advancing toward IND-enabling studies; formulation optimization completed, CMC activities and exploratory repeated-dose toxicology ongoing.
SKNY-1
Preclinical · ActiveModality: oral small molecule
Target CB1 / CB2 / MAO-B
Partnerships SKNY Pharmaceuticals (related party; license acquired September 2025; amended license June 2026)
Indications
obesity(Stage not disclosed)
Status note Preclinical obesity candidate designed to modulate CB1, CB2, and MAO-B pathways. Advancing toward IND-enabling studies.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.